February 16, 2024 / 11:45 IST
Reported Standalone quarterly numbers for Glenmark Pharma are:Net Sales at Rs 1,365.10 crore in December 2023 down 36.84% from Rs. 2,161.47 crore in December 2022.
Story continues below Advertisement
Quarterly Net Loss at Rs. 20.41 crore in December 2023 down 104.74% from Rs. 430.50 crore in December 2022.
EBITDA stands at Rs. 74.55 crore in December 2023 down 85.9% from Rs. 528.57 crore in December 2022.
Glenmark shares closed at 810.25 on February 15, 2024 (NSE) and has given 1.61% returns over the last 6 months and 88.58% over the last 12 months.
| Glenmark Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'23 | Sep'23 | Dec'22 | | Net Sales/Income from operations | 1,365.10 | 2,233.42 | 2,161.47 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 1,365.10 | 2,233.42 | 2,161.47 | | EXPENDITURE | | Consumption of Raw Materials | 701.17 | 807.03 | 711.70 | | Purchase of Traded Goods | 77.72 | 81.23 | 109.77 | | Increase/Decrease in Stocks | -83.94 | 6.08 | 36.18 | | Power & Fuel | -- | -- | -- | | Employees Cost | 379.56 | 383.00 | 357.17 | | Depreciation | 51.16 | 49.85 | 46.22 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 474.85 | 485.23 | 507.82 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -235.43 | 421.01 | 392.62 | | Other Income | 258.82 | 46.22 | 89.73 | | P/L Before Int., Excpt. Items & Tax | 23.39 | 467.22 | 482.35 | | Interest | 73.60 | 58.19 | 55.72 | | P/L Before Exceptional Items & Tax | -50.22 | 409.04 | 426.62 | | Exceptional Items | -25.28 | -19.67 | 162.50 | | P/L Before Tax | -75.50 | 389.37 | 589.13 | | Tax | -55.09 | 87.01 | 158.62 | | P/L After Tax from Ordinary Activities | -20.41 | 302.35 | 430.50 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -20.41 | 302.35 | 430.50 | | Equity Share Capital | 28.22 | 28.22 | 28.22 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.72 | 10.72 | 15.26 | | Diluted EPS | -0.72 | 10.72 | 15.26 | | EPS After Extra Ordinary | | Basic EPS | -0.72 | 10.72 | 15.26 | | Diluted EPS | -0.72 | 10.72 | 15.26 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
